The research advance on the α4β2 acetylcholine receptor and depression
10.16438/j.0513-4870.2018-0322
- VernacularTitle:乙酰胆碱α4β2型受体与抑郁症
- Author:
Zi-ru YU
1
;
Guan-hua DU
1
Author Information
1. Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
- Publication Type:REVIEWS
- Keywords:
α4β2 nicotinic acetylcholine receptor;
cholinergic hypothesis;
depression;
affective disorder
- From:
Acta Pharmaceutica Sinica
2018;53(10):1583-1590
- CountryChina
- Language:Chinese
-
Abstract:
Depression is currently the most popular disease in the world with a high suicide rate. Selective 5-HT reuptake inhibitors have been used as first-line drugs in clinics, but the therapeutic effect is greatly limited. The pathogenesis of depression is complicated, meanwhile the cholinergic hypothesis has received more and more attention. A large number of clinical and preclinical studies have shown that antagonists and partial agonists acting on nicotinic acetylcholine receptors have a significant effect on antidepressant therapy, which can improve the hippocampus recognizes, influence rewards and anxiety systems controlled by the ventral midbrain and ventral tegmental area, and regulate the amygdala pressure system, thereby improving mood and relieving depression. At present, the relationship between the cholinergic system and depression is still undergoing a lot of research. In this article, the relationship between α4β2 nicotinic acetylcholine receptor (nAChRs) and depression is reviewed to provide a reference for study of new anti-depression drugs.
